verifi® Prenatal Test
Verinata Health, Inc. is proud to offer the verifi® prenatal test — a non-invasive prenatal test that detects multiple fetal chromosomal aneuploidies using a single maternal blood draw with near-diagnostic accuracy. If you have ever wanted safer, simpler test results or wished to screen at 10 weeks instead of waiting, now you can order the verifi® prenatal test.
CONTINUOUS INNOVATION
Increased Safety and Peace of Mind for Your Patients
Swift acceptance of the verifi® prenatal test has made a world of difference to high-risk patients across the country:
- SAFE — Routine blood draw, just one tube (7–10 ml)
- ACCURATE — Directly analyzes cell-free fetal DNA with our proprietary SAFeR™ algorithm
- EASY — Test as early as 10 weeks, no limitations in reference to patient ethnicity, BMI, ART or egg donor cases
- COMPREHENSIVE — Capable of aneuploidy detection across the genome
The basic verifi® test detects:
- T21 (Down syndrome)
- T18 (Edwards syndrome)
- T13 (Patau syndrome)
Now a wider option is available for sex chromosomes at no extra charge:
- Monosomy X (MX, Turner syndrome)
- XXX (Trisomy X)
- XXY (Klinefelter syndrome)
- XYY (Jacob’s syndrome)
- Fetal sex (XX or XY) – aids in stratifying the risk for X-linked disorders such as hemophilia, Duchenne muscular dystrophy or cases of ambiguous genitalia, such as congenital adrenal hyperplasia
Test Performance*
As sequencing technology rapidly evolves, our research team has analyzed and implemented several changes to the testing procedure that yield enhanced test performance.
|
||||||||||||||||||||||||||||||||||||||||||||||||
The verifi® test now includes an option for the most common sex aneuploidies, providing information previously known only through invasive results.
|
|||||||||||||||||||||||||||||||||||||||||||||
Sex chromosome mosaicism cannot be distinguished by this method (the occurrence of which is <0.3%). Patients with such mosaicism will have a sex chromosome result reported and will fall into one of the six categories (Monosomy X, XXX, XXY, XYY, XX, XY).
*Test performance data on file.
Intended Use
For patients at 10+ weeks gestation with singleton pregnancies who meet any of the following criteria:
- Advanced maternal age
- Positive results of prenatal aneuploidy screening
- Presence of ultrasound abnormalities
- Previous affected pregnancy for fetal aneuploidy